What Is It, and Why Does It Matter? Fasenra (benralizumab), a targeted medicine called a monoclonal antibody, binds to and reduces levels of eosinophils, a type of immune cell that can cause ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. FASENRA PEN contains the active ingredient benralizumab. FASENRA PEN ...
FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca ...
Benralizumab is now indicated for HES in patients aged ≥12 years when no identifiable non-hematologic secondary cause is present, administered as 30 mg subcutaneously every four weeks.
The FDA has approved an expanded indication of AstraZeneca’s benralizumab (Fasenra) in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results